about
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.Diphenyl difluoroketone: a potent chemotherapy candidate for human hepatocellular carcinomaScreening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review.Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma.Efficacy and safety of oral branched-chain amino acid supplementation in patients undergoing interventions for hepatocellular carcinoma: a meta-analysis.Advances in liver transplantation. New strategies and current care expand access, enhance survival.Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.Radiofrequency ablation combined with transcatheter arterial embolisation in rabbit liver: investigation of the ablation zone according to the time interval between the two therapies.The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells.COMPARATIVE STUDY ON LIVER TRANSPLANTATION WITH AND WITHOUT HEPATOCELLULAR CARCINOMA WITH CIRRHOSIS: ANALYSIS OF MELD, WAITING TIME AND SURVIVAL.Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancerAdaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications.Alpha-1-fucosidase as a prognostic indicator for hepatocellular carcinoma following hepatectomy: a large-scale, long-term study.5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma.Membrane-bound form of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy in a model of hepatocellular carcinoma.Fever after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis.Variable asialoglycoprotein receptor 1 expression in liver disease: Implications for therapeutic intervention.alpha-Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study.Effects of p16 gene on biological behaviours in hepatocellular carcinoma cells.Selection criteria for hepatectomy in patients with hepatocellular carcinoma classified as Child-Pugh class B.Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy.Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma.Hepatocellular carcinoma with lymphoid stroma: a tumour with good prognosis after liver transplantation.[Results of liver transplantation in patients with hepatocellular carcinoma]Cancer-selective induction of cytotoxicity by tissue-specific expression of targeted trans-splicing ribozyme.Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization.Estimate or calculate? How surgeons rate volumes and surfaces.CCL5-28, CCL5-403, and CCR5 genetic polymorphisms and their synergic effect with alcohol and tobacco consumptions increase susceptibility to hepatocellular carcinoma.Hepatocellular carcinoma
P2860
Q33344056-718FDF2B-9711-47AF-B18A-272DABDD4D2FQ34013776-EFCDECD4-4679-4A5A-B8EC-DF9B458044A5Q34984056-64A41F88-54CB-4D85-AD5B-397B7F014900Q35621307-460A94A0-9788-44A0-B60C-B2432CD83793Q35686376-B79C6BD6-6CD5-4ABA-A46D-0FC7A71EA453Q35788569-4C7EF976-FD3C-417A-9C4A-557CCCF51F5FQ36180460-8F1E0BFE-D1C8-4491-B7EB-01D601343AA3Q36407151-E2C9CBDC-E1CE-43AD-9D53-D425FC88D309Q36619843-36C393F6-86DE-474C-B531-0F4FDDCA5840Q36852128-FF3BF49F-D838-406D-B163-6983FA30A3B6Q37495410-3260B721-2D0D-4C98-96D5-09ADB5657A77Q37614595-A8C16BA0-8D38-402A-B5BA-CDD0CEB884ACQ37681702-2D362972-9277-42C7-A05E-355473CEB12AQ38943320-EC01EF33-C2FE-4221-9C26-23A5DD371DCFQ39382979-23F2A4CC-F8F2-4104-966B-0C3B44A9F013Q40402157-956F51D5-A140-4A61-B8BB-EA06DAB4CA84Q40482454-91E0F47B-A8F7-4A57-89C1-E7F1F5A23275Q40650650-EC9741F5-F9B4-4CF4-90D8-CEF23E607BF7Q40679961-61339488-3028-4B3A-96D3-A2BBEBE69A66Q43599811-CE0959B5-0312-44B6-B168-5984D6B8CA31Q43666919-734BC152-FF2E-4E39-AD3D-081AFEED06E1Q44393120-53C660F5-4221-4B65-A122-3BE8084738E9Q44485873-F6D0801F-7304-4E72-B739-7F26EE027595Q45069878-BE6B35DD-89D9-46BF-BC53-8853806913F4Q45862174-1A88CE5A-1CAB-4819-8F9D-B4626F21E8DCQ52933351-2ACEDC4B-83F9-4F57-BF7E-E3E9A1090439Q53097302-F5E3372E-728B-44AE-AA1B-D52514EF2C66Q54321502-86D13A59-DEBF-4FCC-B220-F9B0059EDCABQ57757274-088EE174-38CC-4CE3-89A4-882205653481
P2860
description
im Februar 1997 veröffentlichter wissenschaftlicher Artikel
@de
наукова стаття, опублікована в лютому 1997
@uk
name
Treatment of hepatocellular carcinoma
@en
type
label
Treatment of hepatocellular carcinoma
@en
prefLabel
Treatment of hepatocellular carcinoma
@en
P356
P1433
P1476
Treatment of hepatocellular carcinoma
@en
P2093
P304
P356
10.1002/HEP.510250201
P407
P577
1997-02-01T00:00:00Z